Target intelligence / Profile preview

Potassium voltage-gated channel subfamily H member 3 (KCNH3)

Target
KCNH3
Molecular classification
Ion channel, Voltage-gated potassium channel, Potassium channel
01

Overview

Potassium voltage-gated channel subfamily H member 3 (KCNH3) is a tetrameric transmembrane ion channel from the Kv12.x family (Kv12.2) classified as a voltage-gated potassium channel[2][3]. It is predominantly expressed in the brain and modulates neuronal excitability by permitting selective potassium ion (K⁺) conductance in response to changes in membrane potential, which stabilizes or resets the neuronal membrane after depolarization[2][3]. Structurally, each subunit comprises six transmembrane segments (S1–S6), with the S4 helix serving as the voltage sensor[2]. Upon depolarization, conformational changes shift the channel into its open configuration, allowing K⁺ efflux to repolarize the cell membrane; the channel undergoes rapid gating and inactivation cycles that are critical for precise neuronal signaling[1][2]. Dysfunction or genetic variation in KCNH3 has been implicated in memory deficits, cognitive performance alterations, and increased seizure susceptibility[3]. No drugs are directly targeted to KCNH3 in clinical practice; however, it represents a promising therapeutic target for CNS conditions by virtue of its role in neural circuit modulation[3].

Other names
Voltage-gated inwardly rectifying potassium channel KCNH3KIAA1282BEC1ELK channel 2ELK2Kv12.2Brain-specific eag-like channel 1Ether-a-go-go-like potassium channel 2voltage-gated potassium channel subunit Kv12.2ether-a-go-go K(+) channel family member
02

Mechanism of action

Modulation of potassium ion flux, control of cellular membrane potential, action potential regulation, channel opening/inactivation[1][2]

03

Biological functions

Regulation of neuronal excitabilitySignal transductionModulation of action potential firingControl of neurotransmitter release
04

Disease associations

Neurodegenerative diseaseCognitive disordersEpilepsyOther nervous system disorders
05

Safety considerations

Off-target effects of potassium channel modulators (potential for cardiac arrhythmia, CNS side effects); challenges with selectivity[1][2]
06

Interacting drugs

None specifically approved or established; potassium channel modulators may interact indirectly[2][3]
07

Biomarkers

None specifically established for patient selection or efficacy monitoring[3]

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily H member 3 (KCNH3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily H member 3 (KCNH3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call